Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2026 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
ir@standardbio.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

LAB
The Conversation (0)
Tajiri Resources (TSXV:TAJ)

Tajiri Discovers Potentially Economic Gold Mineralization in Multiple Trenches at Yono Property Including: 12m@ 2.4 g/t; 20m@ 1.4g/t; 8m@ 1.0g/t; 18m@ 0.8g/t & 4m@ 5.5g/t Gold; Bordered by G Mining Ventures Oko West and G2 Goldfields Oko Properties, Guyana

Tajiri Resources Corp. (TSXV: TAJ) ("Tajiri" or the "Company") is pleased to report results from its ongoing Phase II trenching program at the majority owned Yono Project, Guyana, which indicate three significant gold zones potentially hosting economic mineralisation. All results are given in... Keep Reading...
Radisson Highlights Developing Vein Model at O'Brien Gold Project with Implications for Future Growth and Mine Planning

Radisson Highlights Developing Vein Model at O'Brien Gold Project with Implications for Future Growth and Mine Planning

Radisson Mining Resources Inc. (TSXV: RDS,OTC:RMRDF) (OTCQX: RMRDF) ("Radisson" or the "Company") is pleased to present an overview of ongoing geological modelling at its 100%-owned O'Brien Gold Project ("O'Brien" or the "Project") located in the Abitibi region of Québec. This news release... Keep Reading...
Standard Uranium Initiates Winter Drill Program at Corvo Uranium Project, Southeast Athabasca Basin

Standard Uranium Initiates Winter Drill Program at Corvo Uranium Project, Southeast Athabasca Basin

Standard Uranium Ltd. (TSXV: STND,OTC:STTDF) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce that drilling activities have commenced at the Company's 12,364-hectare Corvo Uranium Project ("Corvo", or the "Project") located near Wollaston Lake in... Keep Reading...
Tartisan Nickel (CSE:TN)

Tartisan Nickel Corp. Intersects 11.0 Metres of 1.05% Ni, 0.33% Cu Including 2.0 Metres of 4.79% Ni, 1.25% Cu at the Kenbridge Nickel-Copper-Cobalt Project, Northwestern Ontario

Tartisan Nickel Corp. (CSE: TN,OTC:TTSRF) (OTCQB: TTSRF) (FSE: 8TA) ("Tartisan", or the "Company") is pleased to provide an update on the Company's flagship Kenbridge Nickel-Coppet-Cobalt Project, Sioux Narrows, Ontario. The drill program is designed to test the on strike and down dip potential... Keep Reading...
LAURION Intersects High-Grade Gold and Polymetallic Mineralization in Drill Holes LBX25-101 and LBX25-102 at Ishkoday A-Zone Corridor

LAURION Intersects High-Grade Gold and Polymetallic Mineralization in Drill Holes LBX25-101 and LBX25-102 at Ishkoday A-Zone Corridor

(TheNewswire) Drill Hole LBX25-101 — Highlights 1.50 m @ 0.88 g/t Au, 13.60 g/t Ag, 0.24% Cu, 5.61% Zn (159.20 m to 160.70 m) Including 0.50 m @ 2.06 g/t Au, 31.10 g/t Ag, 0.53% Cu, 12.35% Zn (159.70 m to 160.20 m) 1.60 m @ 1.16 g/t Au, 10.21 g/t Ag, 0.30% Cu, 4.39% Zn (187.70 m to 189.30 m)... Keep Reading...
Double helix DNA with word "ETFs" and biotech stock tickers.

5 Small-cap Biotech ETFs to Watch

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.ETFs are a popular choice as they allow investors to enter the market more safely... Keep Reading...
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study... Keep Reading...
Seegnal Inc

Seegnal Expands Deployment of Seegnal's Prescription Intelligence Platform at Tel Aviv Sourasky Medical Center, a Leading Israeli Public Medical Center and Global Referral Center

Seegnal Inc. (TSXV: SEGN), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced its deepened partnership with Tel Aviv Sourasky Medical Center ("Sourasky Medical Center"). Israel's second-largest public hospital, Sourasky... Keep Reading...
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has closed its previously announced private... Keep Reading...
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with a sole... Keep Reading...
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with Canaccord... Keep Reading...

Interactive Chart

Latest Press Releases

Related News